Anuh Pharma is currently trading at Rs. 149.00, up by 4.05 points or 2.79% from its previous closing of Rs. 144.95 on the BSE.The scrip opened at Rs. 152.70 and has touched a high and low of Rs. 152.85 and Rs. 145.40 respectively. So far 81 shares were traded on the counter.The BSE group `X` stock of face value Rs. 5 has touched a 52 week high of Rs. 173.00 on 14-Nov-2018 and a 52 week low of Rs. 101.25 on 02-Aug-2019.Last one week high and low of the scrip stood at Rs. 161.40 and Rs. 143.75 respectively. The current market cap of the company is Rs. 374.46 crore.The promoters holding in the company stood at 71.78%, while Non-Institutions held 28.22% stake in the company.Anuh Pharma has received European Union Good Manufacturing Practices (EuGMP) Certificate from AEMPS- Spanish Health Authority for five products for the inspection held on November 26, 2018 to November 28, 2018. The products are Erythromycin, Erythromycin Ethyl Succinate, Pyrazinamide, Sulfadoxine and Pyrimethamine.Anuh Pharma is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) and a leading importer, exporter, distributor and manufacturer of bulk drugs, chemicals and pharmaceutical formulations.

Anuh Pharma is currently trading at Rs. 153.00, up by 15.10 points or 10.95% from its previous closing of Rs. 137.90 on the BSE.The scrip opened at Rs. 142.85 and has touched a high and low of Rs. 155.00 and Rs. 138.05 respectively. So far 6089 shares were traded on the counter.The BSE group `X` stock of face value Rs. 5 has touched a 52 week high of Rs. 173.00 on 14-Nov-2018 and a 52 week low of Rs. 101.25 on 02-Aug-2019.Last one week high and low of the scrip stood at Rs. 158.90 and Rs. 137.10 respectively. The current market cap of the company is Rs. 368.32 crore.The promoters holding in the company stood at 71.78%, while Non-Institutions held 28.22% stake in the company. The US Food and Drug Administration (USFDA) has successfully completed an inspection at Anuh Pharma’s facility. The facility was inspected by USFDA from September 16, 2019 to September 20, 2019. At the end of the inspection, no observation (483) was issued. Anuh Pharma is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) and a leading importer, exporter, distributor and manufacturer of bulk drugs, chemicals and pharmaceutical formulations.

Anuh Pharma is currently trading at Rs. 110.00, up by 0.75 points or 0.69% from its previous closing of Rs. 109.25 on the BSE.The scrip opened at Rs. 109.00 and has touched a high and low of Rs. 111.40 and Rs. 105.15 respectively. So far 2391 shares were traded on the counter.The BSE group `X` stock of face value Rs. 5 has touched a 52 week high of Rs. 189.80 on 31-Aug-2018 and a 52 week low of Rs. 101.25 on 02-Aug-2019.Last one week high and low of the scrip stood at Rs. 125.00 and Rs. 101.25 respectively. The current market cap of the company is Rs. 276.24 crore.The promoters holding in the company stood at 71.78% while Non-Institutions held 28.22% stake in the company. Anuh Pharma has received approval from WHO - Geneva Prequalification that the Prequalification Inspection Group has recommended that the API`s Pyrimethamine, Pyrazinamide and Sulfadoxine can be considered to be compliant with the standards of Good Manufacturing Practices (GMP) for Active Pharmaceutical Ingredients (APIs) published by the World Health Organisation (WHO) for manufacturing and packaging of APIs by chemical synthesis.Anuh Pharma is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) and a leading importer, exporter, distributor and manufacturer of bulk drugs, chemicals and pharmaceutical formulations.

A decent increase of about 46.03% in the sales to Rs. 802.49 millions was observed for the quarter ended June 2018. The sales figure stood at Rs. 549.54 millions during the year-ago period.Net profit declined -8.94% to Rs. 56.97 millions from Rs. 62.56 millions.Operating profit for the quarter ended June 2018 decreased to 80.53 millions as compared to 80.91 millions of corresponding quarter ended June 2017. (Rs. in Million) Quarter ended Year to Date Year ended 201806 201706 % Var 201806 201706 % Var 201803 201703 % Var Sales 802.49 549.54 46.03 802.49 549.54 46.03 2412.36 2169.54 11.19 Other Income 11.47 33.93 -66.20 11.47 33.93 -66.20 73.90 75.91 -2.65 PBIDT 80.53 80.91 -0.47 80.53 80.91 -0.47 252.89 295.98 -14.56 Interest 0.08 0.00 0.00 0.08 0.00 0.00 0.41 0.44 -6.82 PBDT 80.45 80.91 -0.57 80.45 80.91 -0.57 252.48 295.54 -14.57 Depreciation 3.52 4.15 -15.18 3.52 4.15 -15.18 18.31 19.68 -6.96 PBT 76.93 76.76 0.22 76.93 76.76 0.22 234.17 275.86 -15.11 TAX 19.96 14.20 40.56 19.96 14.20 40.56 69.05 75.35 -8.36 Deferred Tax -1.32 0.00 0.00 -1.32 0.00 0.00 0.45 -0.95 -147.37 PAT 56.97 62.56 -8.94 56.97 62.56 -8.94 165.12 200.51 -17.65 Equity 125.28 125.28 0.00 125.28 125.28 0.00 125.28 125.28 0.00 PBIDTM(%) 10.04 14.72 -31.84 10.04 14.72 -31.84 10.48 13.64 -23.16

The company witnessed a 11.81% growth in the revenue at Rs. 633.29 millions for the quarter ended December 2017 as compared to Rs. 566.39 millions during the year-ago period.A humble growth in net profit of 13.27% reported in the quarter ended December 2017 to Rs. 49.34  millions from Rs. 43.56 millions.The company reported a good operating profit of 71.33 millions compared to 63.72 millions of corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201712 201612 % Var 201712 201612 % Var 201703 201603 % Var Sales 633.29 566.39 11.81 1734.71 1592.16 8.95 2169.54 3417.16 -36.51 Other Income 15.69 12.24 28.19 67.19 47.97 40.07 45.99 35.07 31.14 PBIDT 71.33 63.72 11.94 221.58 195.59 13.29 271.26 402.39 -32.59 Interest 0.03 0.04 -25.00 0.04 0.14 -71.43 0.44 0.43 2.33 PBDT 71.30 63.68 11.97 221.53 195.45 13.34 270.82 401.96 -32.63 Depreciation 4.43 5.15 -13.98 13.09 14.45 -9.41 19.68 22.59 -12.88 PBT 66.87 58.53 14.25 208.44 181.00 15.16 251.14 379.37 -33.80 TAX 17.53 14.97 17.10 53.52 49.92 7.21 75.35 121.33 -37.90 Deferred Tax -0.17 -0.03 466.67 4.22 -0.08 -5375.00 -0.95 -4.67 -79.66 PAT 49.34 43.56 13.27 154.92 131.08 18.19 175.79 258.04 -31.87 Equity 125.28 125.28 0.00 125.28 125.28 0.00 125.28 125.28 0.00 PBIDTM(%) 11.26 11.25 0.12 12.77 12.28 3.98 12.50 11.78 6.18

Anuh Pharma has informed that the inspection of manufacturing site of Anuh Pharma Ltd. at E-17/3 and E-17/4, M.I.D.C. Tarapur, Taluka Palghar, District Thane 401506, Boisar, Maharashtra, India on September 16, 2016 by World Health Organisation (WHO) Geneva for the Pyrazinamide APIMF158 and Sulfadoxine APIMF234. Considers the site in compliance to WHO GMPs for above mentioned Active Pharmaceutical Ingredients.The above information is a part of company’s filings submitted to BSE.

Anuh Pharma has informed that the inspection of manufacturing site of Anuh Pharma at E-17/3 and E-17/4, M.I.D.C. Tarapur, Taluka Palghar, District Thane 401506, Boisar, Maharashtra, India on September 16, 2016 by French Naional Agency for Medicines and Health Products Safety (ANSM) for the Erythromycin Ethyl Succinate and Pyrazinamide. Considers the site in compliance with principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC and has granted EUGMP Certificate for the above mentioned products.The above information is a part of company’s filings submitted to BSE.

Anuh Pharma has informed about the details of voting results at the 56th Annual General Meeting (AGM) of the Company held on September 23, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizers Report and Proceedings of the Meeting in this regard.The above information is a part of company’s filings submitted to BSE.

Anuh Pharma has informed that the 56th Annual General Meeting (AGM) of the Company was held on September 23, 2016.The above information is a part of company’s filings submitted to BSE.

Anuh Pharma has informed that the Board of Directors of the Company at its meeting held on March 11, 2016,has declared an Interim Dividend of Rs 2 per Equity Share of face value of Rs 5 each i.e. 40% for the Financial Year 2015-16.The above information is a part of company’s filings submitted to BSE.

Anuh Pharma has submitted a copy of the company’s investor presentation.The above information is a part of company’s filings submitted to BSE.

Anuh Pharma has informed that Jayantilal P. Shah, Non-Executive Director (Promoter Director) of the Company has passed away on January 09, 2016. Jayantilal P. Shah provided invaluable advice and guidance to the Company. His contribution will be missed by the Employees, Management and Board of the Company.The above information is a part of company’s filings submitted to BSE.